View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 2, 2017

Asuragen launches new response monitoring kit for CML

US-based molecular diagnostics firm Asuragen has launched the QuantideX qPCR BCR-ABL minor Kit designed to monitor molecular response in patients with chronic myeloid leukaemia (CML).

US-based molecular diagnostics firm Asuragen has launched the QuantideX qPCR BCR-ABL minor Kit designed to monitor molecular response in patients with chronic myeloid leukaemia (CML).

Based on its predecessor, QuantideX qPCR BCR-ABL IS Kit, which quantifies major BCR-ABL1 fusion transcripts in the disease, the new kit will measure minor BCR-ABL1 fusion transcripts.

Asuragen diagnostic systems feature a combination of chemistry and software to provide simple and reliable performance through instrument platforms.

The QuantideX BCR-ABL line is intended to allow laboratories to monitor patients with leukaemia, enabling them to obtain the latest tyrosine-kinase inhibitor (TKI) treatments.

With multiplexed assay design, the kits use a single reaction to identify fusion transcripts and controls, while their Armored RNA-based standards ensure precise RNA quantification.

"The expanded QuantideX BCR-ABL portfolio demonstrates our commitment and focus on changing how diagnostics impact care."

Asuragen president and CEO Matthew McManus said: “For CML patients with sustained responses to TKI therapy, the goal of treatment-free remission is gaining momentum in the clinical community.

“Monitoring during therapy cessation will require accurate, reproducible, and highly sensitive measurement of disease burden.

“The expanded QuantideX BCR-ABL portfolio demonstrates our commitment and focus on changing how diagnostics impact care.”

Both the major and minor kits are reported to possess clinical sensitivities that can identify even 0.002% and 0.0025% ratio of residual disease amounts using human RNA.

Following a review of ABL1 copy number, the firm is also increasing the capabilities of QuantideX qPCR BCR-ABL IS Kit’s accompanying analysis software QuantideX Reporter to enable reporting of accurate clinical sensitivity for CML patient disease burden.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU